#Biotech

Chinese state-backed investors are pouring funds into AI-driven drug developers as Beijing pushes technological self-reliance. One company has already reached Phase III trials with an AI-designed therapy.

Artificial intelligence is addressing the talent shortage in drug discovery, offering new hope for thousands of untreated rare diseases through automated research and gene editing.

Harvard professor's biotech startup wins FDA approval for humanity's first age reversal clinical trial using cellular reprogramming technology. Can we actually turn back time?

With over 2,500 US measles cases since 2025, measles wastewater surveillance 2026 emerges as a critical tool, detecting outbreaks a week before clinical diagnoses.

Explore the case of a 63-year-old man facing multi-organ failure due to a hypervirulent bacteria infection in 2026. Analysis of the global rise of aggressive pathogens.

Chai Discovery lands a $1.3B valuation and partners with Eli Lilly for AI-powered drug discovery. Explore the OpenAI-backed startup's journey and its Chai-2 algorithm.

Explore the breakthrough in iPS cell heart therapy by Heartseed and the latest cancer survival statistics as of January 2026.

Merck (MSD) announced a revenue target of $70 billion by the mid-2030s, driven by new growth opportunities and a diversified pipeline to offset Keytruda's patent expiration.

Chinese researchers at the Kunming Institute of Zoology successfully reversed Alzheimer's symptoms in mice by restoring brain glucose levels via the GLUT1 protein.

China enters 'Biotech Innovation 2.0', focusing on commercialization to challenge US market dominance despite growing trade restrictions.

Genmab has discontinued the development of an experimental cancer therapy. Reuters reports a shift in focus to more promising assets within the Danish biotech's pipeline.

Insilico Medicine goes public in Hong Kong, unveiling its 'digital Einstein' AI to tackle the 90% failure rate in the 'molecular casino' of drug discovery.